Page 90 - Read Online

Zhang et al. Cancer Drug Resist 2024;7:34 Cancer
DOI: 10.20517/cdr.2024.59
Drug Resistance

Review Open Access

Non-coding RNA and drug resistance in head and
neck cancer

3
1,2
1
1
1,#
1,#
Yulong Zhang , Yingming Peng , Bingqin Lin 1,2,# , Shuai Yang , Feiqiang Deng , Xuan Yang , An Li ,
1
1
1
4
Wanyi Xia , Chenxi Gao , Shaona Lei , Wei Liao , Qi Zeng 1,2
1
Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong, China.
2
Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Infectious Diseases, Traditional Chinese
Medicine Bureau of Guangdong Province, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, Guangdong,
China.
3
Department of Radiotherapy and Minimally Invasive Surgery, Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen
University, Zhuhai 519000, Guangdong, China.
4
Department of Otolaryngology and Head and Neck Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai
519000, Guangdong, China.
#
Authors contributed equally.
Correspondence to: Prof. Zeng Qi, Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Meihua East Street,
Zhuhai 519000, Guangdong, China. E-mail: zengqi37@mail.sysu.edu.cn; Wei Liao, Department of Otolaryngology and Head and
Neck Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Meihua East Street, Zhuhai 519000, Guangdong, China. E-
mail: liaowei23@mail.sysu.edu.cn
How to cite this article: Zhang Y, Peng Y, Lin B, Yang S, Deng F, Yang X, Li A, Xia W, Gao C, Lei S, Liao W, Zeng Q. Non-coding
RNA and drug resistance in head and neck cancer. Cancer Drug Resist 2024;7:34. https://dx.doi.org/10.20517/cdr.2024.59
Received: 14 May 2024 First Decision: 1 Aug 2024 Revised: 17 Aug 2024 Accepted: 29 Aug 2024 Published: 20 Sep 2024
Academic Editors: Hailin Tang, Godefridus J. Peters Copy Editor: Dong-Li Li Production Editor: Dong-Li Li
Abstract
Head and neck cancer (HNC) is ranked as the sixth most common malignant tumor, and the overall survival rate
with current treatment options remains concerning, primarily due to drug resistance that develops following
antitumor therapy. Recent studies indicate that non-coding RNAs play a crucial role in drug resistance among HNC
patients. This article systematically reviews the current research landscape, explores novel targets and treatment
strategies related to non-coding RNAs and HNC resistance, raises some unresolved issues, and discusses five
promising research directions in this field: ferroptosis, nanomedicine, exosomes, proteolysis-targeting chimeras
(PROTACs), and artificial intelligence. We hope that our work will contribute to advancing research on overcoming
HNC resistance through the regulation of non-coding RNAs.

Keywords: Head and neck cancer, non-coding RNA, microRNA, long non-coding RNA, circular RNA, drug
resistance

© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing,
adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as
long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made.

www.oaepublish.com/cdr